The European Technology Platform on Nanomedicine (ETPN) finds the new EU pharmaceutical legislation largely aligned with its objectives of enhancing drug availability, accessibility, and innovation. It commends the efforts to expedite EMA authorization timelines and address drug shortages but suggests greater industrial accountability and supply chain security strategies.
ETP
European Technology Platform on Nanomedicine (ETPN)
Industry association · France
not in the EU Transparency RegisterThis organization files on consultations without a register number, so its record here is built from its filings alone. Register facts (staff, costs, accreditations) are not available for it.
2
positions filed
in the 687 files tracked
2
legislative files
of 687 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 687 consultation files tracked so far (60,344 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Track European in PolicySpeak: request access →
Work at European Technology Platform on Nanomedicine (ETPN)? so we know who speaks for it.
Their record over time
European Technology Platform on Nanomedicine (ETPN) filed 2 positions between 3 Mar 2020 and 7 Nov 2023, across 2 of the 687 legislative files tracked here, attaching a full position paper 1 time.
2020 · 1 filed2023 · 1 filed
What they argued
The European Technology Platform on Nanomedicine (ETPN) strongly supports and endorses the proposed roadmap for Europe’s Beating Cancer Plan. It focuses on four pillars: prevention, early diagnosis, treatment & social aspects, including equal access to quality and affordable cancer care across Europe.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put European Technology Platform on Nanomedicine (ETPN) next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 45.
Is this your organization?
Everything on this page comes from European Technology Platform on Nanomedicine (ETPN)’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.